中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢性乙型肝炎抗病毒治疗Treat all时代离我们还有多远?

丁洋 窦晓光

丁洋, 窦晓光. 慢性乙型肝炎抗病毒治疗Treat all时代离我们还有多远?[J]. 临床肝胆病杂志, 2021, 37(11): 2546-2547. DOI: 10.3969/j.issn.1001-5256.2021.11.011
引用本文: 丁洋, 窦晓光. 慢性乙型肝炎抗病毒治疗Treat all时代离我们还有多远?[J]. 临床肝胆病杂志, 2021, 37(11): 2546-2547. DOI: 10.3969/j.issn.1001-5256.2021.11.011
DING Y, DOU XG. How far are we from the 'Treat all' era of antiviral therapy for chronic hepatitis B[J]. J Clin Hepatol, 2021, 37(11): 2546-2547. DOI: 10.3969/j.issn.1001-5256.2021.11.011
Citation: DING Y, DOU XG. How far are we from the "Treat all" era of antiviral therapy for chronic hepatitis B[J]. J Clin Hepatol, 2021, 37(11): 2546-2547. DOI: 10.3969/j.issn.1001-5256.2021.11.011

慢性乙型肝炎抗病毒治疗Treat all时代离我们还有多远?

DOI: 10.3969/j.issn.1001-5256.2021.11.011
详细信息
    通讯作者:

    窦晓光,guang40@163.com

  • 中图分类号: R512.62

How far are we from the "Treat all" era of antiviral therapy for chronic hepatitis B

  • [1] Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [2] CORNBERG M, SANDMANN L, PROTZER U, et al. S3-Leitlinie der deutschen gesellschaft für gastroenterologie, verdauungs-und stoffwechselkrankheiten (DGVS) zur prophylaxe, diagnostik und therapie der hepatitis-B-virusinfektion-(AWMF-Register-Nr. 021-11)[J]. Z Gastroenterol, 2021, 59(7): 691-776. DOI: 10.1055/a-1498-2512.
    [3] CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311.
    [4] GUI HL, WANG H, YANG YH, et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase[J]. J Viral Hepat, 2010, 17(Suppl 1): 44-50. DOI: 10.1111/j.1365-2893.2010.01270.x.
    [5] KIM JH, SINN DH, KANG W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2): 335-343. DOI: 10.1002/hep.28916.
    [6] FAN YX, DOU XG. Optimal timing significance and clinical implications for the treatment of chronic HBV-infected patients with normal ALT[J]. Chin J Hepatol, 2020, 28(11): 170-172. DOI: 10.3760/cma.j.cn501113-20201026-00579.

    樊耀昕, 窦晓光. ALT正常的慢性HBV感染者疾病评估及治疗时机选择[J]. 中华肝脏病杂志, 2020, 28(11): 170-172. DOI: 10.3760/cma.j.cn501113-20201026-00579.
    [7] CHU CM, LIAW YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus[J]. Am J Gastroenterol, 2009, 104(7): 1693-1699. DOI: 10.1038/ajg.2009.187.
    [8] HAN C, DOU XG. Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: Consensus and contention[J]. Chin J Hepatol, 2021, 4(29): 192-195. DOI: 10.3760/cma.j.cn501113-20210326-00139.

    韩超, 窦晓光. 口服NAs抗病毒治疗降低HBV相关肝细胞癌: 共识与争鸣[J]. 中华肝脏病杂志, 2021, 4(29): 192-195. DOI: 10.3760/cma.j.cn501113-20210326-00139.
    [9] FANNING GC, ZOULIM F, HOU J, et al. Therapeutic strategies for hepatitis B virus infection: Towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11): 827-844. DOI: 10.1038/s41573-019-0037-0.
  • 加载中
计量
  • 文章访问数:  163
  • HTML全文浏览量:  23
  • PDF下载量:  69
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-09-14
  • 录用日期:  2021-09-14
  • 出版日期:  2021-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回